Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | India
Approved Indications: None
Known Adverse Events: None
Company: Elysium Health
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Kidney Injury
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04342975 |
NCT04342975 | P2 |
Completed |
Acute Kidney Injury |
2024-03-14 |
50% |
2024-04-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/08/2025 |
News Article |
Best Cellular Repair Supplement with Lifespan-Extending Nutrients for Longevity & Healthy Cell Function |
|
12/19/2024 |
News Article |
STEMREGEN® Partners with Iconic Athlete and Wellness Advocate Gabby Reece |
|
11/19/2024 |
News Article |
Amid 34% Market Growth, Gaspari Nutrition Expands Legendary Sizeon Line with New Raspberry Formula |
|
11/15/2024 |
News Article |
Clinical Trial Confirms Efficacy of Senolytic Agent PCC and Cellumiva(TM) |
|
05/02/2024 |
PubMed |
Comparative analyses of anti-inflammatory effects of Resveratrol, Pterostilbene and Curcumin: in-silico and in-vitro evidences. |
|
05/01/2024 |
PubMed |
Reversal of Obesity by Enhancing Slow-wave Sleep via a Prokineticin Receptor Neural Circuit. |
|
05/01/2024 |
PubMed |
Inhibition of UVB radiation-induced tissue swelling and immune suppression by nicotinamide riboside and pterostilbene. |